Noopept (GVS-111 / Omberacetam)
Synthetic peptide nootropic and dipeptide analogue of piracetam. Acts via BDNF/NGF upregulation and AMPA/NMDA receptor modulation. Extremely potent by weight (~1000x piracetam). Parent compound has very short half-life but active metabolite cycloprolylglycine mediates sustained effects.
Projected serum levels — 10 mg, once daily
Maintenance schedule: 10 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 0.45 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Nootropic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 1.4 h
- Common dose
- 10 mg
- Suggested maximum
- 30 mg/day
- Reference dose range
- 5–30 mg (single dose)
- Suggested cadence
- once daily
Documented interactions
-
watch
Selank + Noopept (GVS-111 / Omberacetam)
Noopept (GVS-111 / Omberacetam) and Selank both push the bdnf signaling in the same direction.
-
watch
Semax + Noopept (GVS-111 / Omberacetam)
Noopept (GVS-111 / Omberacetam) and Semax both push the bdnf signaling in the same direction.
Serum checks 3 modeled interaction pairings for noopept (gvs-111 / omberacetam) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Noopept pretreatment protected PC12 cells against amyloid-beta toxicity by inhibiting oxidative damage, calcium overload, and suppressing the mitochondrial apoptotic pathway, with significant attenuation of tau…
-
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
Chronic noopept administration restored spatial memory in a bulbectomized Alzheimer model and increased amyloid immunoreactivity, suggesting both cognitive enhancement and amyloid clearance properties.
-
GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons
GVS-111 provided significant neuroprotection against oxidative stress-induced apoptosis in both normal and Down syndrome human cortical neurons, supporting its potential as a broad-spectrum neuroprotectant.
3 published studies referenced in the app, each with a plain-language summary.